Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators  by Tanaka, Masashi et al.
Cardiothoracic Transplantation Tanaka et al
TXInhibition of heart transplant injury and graft coronary
artery disease after prolonged organ ischemia by selective
protein kinase C regulators
Masashi Tanaka, MD,a Feny Gunawan,a Raya D. Terry,a Koichi Inagaki, MD, PhD,b Anthony D. Caffarelli, MD,aGrant Hoyt,a Philip S. Tsao, PhD,c Daria Mochly-Rosen, PhD,b and Robert C. Robbins, MDaFrom the Departments of Cardiothoracic
Surgery,a Molecular Pharmacology,b and
Cardiovascular Medicine,c Stanford Uni-
versity Medical Center, Stanford, Calif.
Supported by National Institutes of Health
grants HL65669 (R.C.R.) and HL52141
(D.M.-R.).
D.M.-R. is a founder of KAI Pharmaceuti-
cals, the goal of which is to bring peptide
regulators of PKC to the clinic. The re-
search described in this study, however,
was performed in collaboration with her
laboratory at the university with sole sup-
port from the National Institutes of Health
to her university activities.
Received for publication June 17, 2004;
revisions received Sept 8, 2004; accepted
for publication Sept 20, 2004.
Address for reprints: Masashi Tanaka, MD,
Department of Cardiothoracic Surgery,
Stanford University School of Medicine,
Falk Cardiovascular Research Center, Stan-
ford, CA 94305 (E-mail: masahi@
omiya.jichi.ac.jp).
J Thorac Cardiovasc Surg 2005;129:1160-7
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgery
Dr Tanakadoi:10.1016/j.jtcvs.2004.09.015
1160 The Journal of Thoracic and CardObjective: Transplanted hearts subjected to prolonged ischemia develop ischemia-
reperfusion injury and graft coronary artery disease. To determine the effect of
-protein kinase C and -protein kinase C on ischemia-reperfusion injury and the
resulting graft coronary artery disease induced by prolonged ischemia, we used a
-protein kinase C–selective inhibitor peptide and an -protein kinase C–selective
activator peptide after 30 or 120 minutes of ischemia.
Methods: Hearts of piebald viral glaxo (PVG) rats were heterotopically transplanted
into allogeneic August Copenhagen Irish (ACI) rats. After cardioplegic arrest of the
donor heart, -protein kinase C activator was injected antegrade into the coronary
arteries. Hearts were procured and bathed in -protein kinase C activator, and before
reperfusion, -protein kinase C inhibitor was injected into the recipient inferior vena
cava. Controls were treated with saline. To analyze ischemia-reperfusion injury,
grafts were procured at 4 hours after transplantation and analyzed for superoxide
generation; myeloperoxidase activity; tumor necrosis factor , interleukin 1, and
monocyte/macrophage chemoattractant protein 1 production; and cardiomyocyte
apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end label-
ing and caspase 2, 3, 8, and 9 activity. To analyze graft coronary artery disease,
another set of animals underwent equal ischemic times and treatment strategies and
then after 90 days were analyzed for graft coronary artery disease indexes.
Results: All measures of ischemia-reperfusion injury and graft coronary artery
disease after 120 minutes of ischemia in the saline-treated group were significantly
increased relative to those observed after 30 minutes of ischemia. It is important to
note that all ischemia-reperfusion injury parameters and graft coronary artery
disease indexes decreased significantly in the protein kinase C regulator–treated
group in comparison to saline-treated controls; additionally, these values were
equivalent to those in saline-treated controls with 30 minutes of ischemia.
Conclusions: Combined treatment with -protein kinase C activator and -protein
kinase C inhibitor reduces ischemia-reperfusion injury and decreases the resulting
graft coronary artery disease induced by prolonged ischemia.
Despite recent advances in immunosuppressive therapy and in the treatmentand diagnosis of posttransplantation infection–induced complications andacute rejection, graft coronary artery disease (GCAD) remains the leading
cause of death in patients who survive more than 1 year after cardiac transplanta-
tion.1 The development of GCAD in heart transplant patients is currently inevitable,
and, unlike with typical coronary artery disease, there is no effective treatment other
than retransplantation. The pathophysiological processes that contribute to the
initiation and propagation of GCAD, although not completely understood, are
multifactorial and likely involve both alloantigen-independent and alloantigen-
dependent mechanisms.2
Ischemia-reperfusion injury was the strongest alloantigen-independent factor for the
subsequent development of GCAD in a clinical case-control study.3 Wang and col-
leagues4 have shown that ischemia-reperfusion injury alone can promote alloantigen-
independent formation of GCAD. Ischemia-reperfusion injury generates an inflamma-
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TXtory environment, which includes the production of the
injurious chemokines and cytokines—such as tumor necrosis
factor (TNF)-, interleukin (IL)-1, and monocyte/macro-
phage chemoattractant protein (MCP)-1—and which leads to
graft failure.5 In addition, numerous studies have shown that
cardiomyocyte apoptosis is an early event in cardiac ischemia-
reperfusion injury,6 which led to our hypothesis that early
prevention of cardiomyocyte apoptosis should reduce isch-
emia-reperfusion injury in the transplanted heart and the sub-
sequent development of GCAD.
The protein kinase C (PKC) family of highly homologous
enzymes is involved in a variety of cellular functions.7 We
have shown that treatment with an PKC-selective activator
peptide, RACK (receptor for activated C kinase), or a
PKC-selective inhibitor peptide, V1-1, alone conferred car-
dioprotection to the ischemic heart.8,9 We have also shown that
combined treatment with these 2 PKC regulator peptides pro-
vides greater cardioprotection against ischemia-reperfusion in-
jury than treatment with the individual peptide treatments
alone in isolated perfused rat hearts and transgenic mice.10
Moreover, we have recently found that these PKC regulating
peptides reduced 50-minute ischemia–induced injury and the
subsequent development of GCAD in murine cardiac allografts
when measured 30 days after transplantation.11 In that study,
we delivered the PKC activator to the donor 20 minutes
before organ harvest, and the PKC inhibitor was delivered to
the recipient abdominal cavity, as opposed to the graft itself.
Neither of these delivery routes was likely applicable to the
clinical situation. In addition, the effects of these PKC-regu-
lating peptides on ischemia-reperfusion injury and the GCAD
induced by prolonged ischemia have not yet been determined.
Our hypothesis is that treatment with PKC regulators in a
clinically relevant protocol will reduce both immediate isch-
emia-reperfusion injury and the resulting development of
GCAD. Using the previously described selective PKC isozyme
regulator peptides, we tested this hypothesis in a rat cardiac
allograft model subjected to up to 120 minutes of ischemia and
measured the development of GCAD 90 days after transplan-
tation.
Materials and Methods
Animals
Adult male inbred piebald viral glaxo (PVG; RT1c) and August
Copenhagen Irish (ACI; RT1a) rats weighing 200 to 250 g were
purchased from Harlan Sprague-Dawley (Indianapolis, Ind). The
PVG rats were used as allograft donors, and the ACI rats were used
as recipients. All rats were kept under standard temperature, hu-
midity, and timed-lighting conditions and were provided rat chow
and water ad libitum. Animals were housed and cared for in
compliance with the Guide for the Care and Use of Laboratory
Animals prepared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National Acad-
emy Press (revised 1996).
The Journal of ThoracicHeterotopic Cardiac Transplantation
Donor PVG hearts were heterotopically transplanted into the
abdomen of ACI recipients as previously described by Ono and
Lindsey.12 Briefly, the donor heart was induced into cardiac
arrest by injection of ice-cold high-potassium cardioplegia so-
lution into the aortic root. The procured hearts were allowed to
incubate in a bath of cold saline. After the recipient was
anesthetized with 2.5% inhaled isoflurane (Halocarbon Labora-
tories, River Edge, NJ) and intraperitoneal sodium pentobarbi-
tal 40 mg/kg (Abbott Laboratories, North Chicago, Ill), the
donor ascending aorta and pulmonary artery were anastomosed
to the infrarenal abdominal aorta and inferior vena cava, re-
Figure 1. Selective PKC regulators inhibit cardiomyocyte apopto-
sis, but not superoxide radical production, induced by ischemia-
reperfusion injury to transplanted hearts subjected to 30 or 120
minutes of ischemia. A, Superoxide production. B, In situ oligo
ligation (ISOL) TUNEL-positive cell counts. Closed columns, Con-
trol group (n  6 for each ischemic time); open columns, PKC
regulator–treated group (n  6 for each ischemic time); N.S., not
significant. Values obtained from naive hearts of PVG rats (con-
trol; no ischemia) served as a reference (n  4). Mean  SE
values are shown.spectively.
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In the treated groups, after cardioplegic arrest of the donor heart
and ligation of the ascending aorta, 2 mL of PKC activator
(RACK; 1.5 nmol) solution was injected antegrade into the
coronary artery system. Hearts were then procured and submerged
in PKC activator (RACK; 0.5 mol/L) solution for 10 or 100
minutes at 4°C. Because standard graft implantation averages
approximately 20 minutes, total ischemic times were 30 and 120
minutes. Before reperfusion of the donor heart, 1 mL of PKC
inhibitor (V1-1; 30 nmol) solution was injected into the recipient
inferior vena cava. Control animals were treated with normal
saline.
Experimental Groups
This was a 2-part study. In the first part, indicators of ischemia-
reperfusion injury were analyzed after 4 hours of reperfusion (n 
6 for each ischemic time). In the second part, GCAD was evalu-
ated at 90 days (n  8 for each ischemic time). In the latter group,
recipients received cyclosporine A (7.5 mg/kg oral gavage) on
postoperative days 0 to 9 to inhibit acute rejection.
Superoxide Production
Superoxide levels were measured in excised tissue by the spin trap
method after 4 hours of reperfusion. Superoxide accumulation was
measured by using conditioned medium supplemented with the
spin trapping agent 4-amino-2,2,6,6,-tetramethylpiperidine-1-oxyl
(tempamine, Sigma-Aldrich, St Louis, Mo), as previously de-
scribed.13 Electron paramagnetic resonance (EPR) spectra were
recorded at room temperature with a spectrometer (model 8400;
Resonance Instruments, Skokie, Ill). The EPR signal intensity was
quantified by comparing the double integration of the recorded
first-derivative EPR peaks of each sample with that of a standard
tempamine spin solution. When tempamine reacts with another
radical species, such as superoxide, it loses its EPR signal. Thus,
the reduction in peak height is directly proportional to the amount
of superoxide produced. All measurements were normalized to the
protein concentration of each sample as determined by the bicin-
choninic acid method (Pierce Chemical, Rockford, Ill).
In Situ Oligo Ligation Terminal Deoxynucleotidyl
Transferase-Mediated dUTP Nick End Labeling
Analysis
Apoptotic cardiomyocyte counts in allograft tissues were deter-
mined by in situ staining of DNA strand breaks in serial sections
of each specimen with the use of an ApopTag in situ oligo ligation
kit with oligo A (Intergen, Purchase, NY), as previously de-
scribed.14 Because conventional terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling (TUNEL) assay can de-
tect nonspecific DNA fragmentation due to necrosis, a more
specific in situ ligation assay for identifying apoptotic nuclei was
used with hairpin oligonucleotide probes. Cardiomyocyte apopto-
sis was confirmed by double-staining the sections with -sarco-
meric actin (Sigma). The number of TUNEL-positive cardiomyo-
cytes in each cardiac allograft was counted manually by 2
investigators (F.G. and R.D.T.) blinded to the experimental con-
ditions. Cells were counted in 6 animals (4 fields each) at 200
magnification. The percentage of TUNEL-stained cells was re-
1162 The Journal of Thoracic and Cardiovascular Surgery ● Macorded, ie, the number of labeled nuclei divided by the total
number of nuclei.
Enzyme-Linked Immunosorbent Assay, Caspase
Activity, and Myeloperoxidase Assays
Snap-frozen myocardial tissue specimens were homogenized in
phosphate-buffered saline and centrifuged at 12,000g for 20
minutes at 4°C. The protein concentration of the supernatant
was determined by the bicinchoninic acid method, and aliquots
were stored at 80°C. Intragraft TNF-, IL-1, and MCP-1/
CCL-2 (BioSource International, Camarillo, Calif) and caspase
2, 8, and 9 activity assay kits were obtained from R&D Systems
(Minneapolis, Minn). The caspase 3 activity assay kit was
purchased from BD Biosciences (Palo Alto, Calif). Myeloper-
oxidase (MPO) activity (as units per milligram of total protein)
was assessed in the lysates of reperfused cardiac allografts as
previously described.15
Morphometric Analysis of GCAD
At 90 days after transplantation, the cardiac grafts were harvested
and embedded in paraffin. Elastica van Gieson staining was per-
formed for morphometric analysis of arterial intimal proliferation,
which was performed as described previously.16 In brief, the
neointima, media, and lumen were measured with SPOT Ad-
vanced version 3.4.2 software (Diagnostic Instruments, Inc,
Sterling Heights, Mich). The neointima was defined as the area
bounded by the internal elastic lamina, the media as the region
between the internal and external elastic membranes, and the
lumen as the clear region in the vessel. Diseased vessels were
identified by greater than 10% luminal narrowing. Multiple sec-
tions from the middle of the heart were used for analysis. Middle-
sized coronary arteries were analyzed (more than 10 arteries for
each graft).
Statistical Analysis
All results are expressed as mean  SE. Data were compared, and
between-group differences were analyzed by analysis of variance
with a post hoc Bonferroni test. Statistical analyses were per-
formed with StatView 5.0 (SAS Institute, Cary, NC).
Results
Reduction of Cardiomyocyte Apoptosis With
Prolonged Ischemia to the Levels of Those With Short
Periods of Ischemia by Treatment With PKC
Regulators During Ischemia-Reperfusion Injury
We first measured superoxide production, because myocar-
dial injury after ischemia-reperfusion is mediated by oxy-
gen-derived free radicals such as superoxide anion.17 Four
hours after reperfusion, we found a 1.3-fold increase in
superoxide production in the transplanted hearts after 120
minutes of ischemia as compared with the hearts subjected
to a 30-minute ischemia in both the PKC regulator–treated
and the control groups. However, similar production of
superoxide occurred in both the treatment and control
groups (Figure 1, A). Because ischemia-reperfusion injury
causes cardiomyocyte apoptosis in the cardiac allografts,6
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apoptosis in cardiac allografts. Four hours after reperfusion,
the number of apoptotic cardiomyocytes increased 2.2-fold
in the control group subjected to 120 minutes of ischemia as
compared with the control group subjected to 30 minutes of
ischemia. In addition, the PKC regulator treatments reduced
the number of apoptotic cardiomyocytes in cardiac allo-
grafts subjected to 120 minutes of ischemia by approxi-
mately 40%, similar to the reduction observed in cardiac
allografts subjected to only 30 minutes of ischemia (Figure
1, B). Paralleling the increased number of apoptotic cardi-
omyocytes, caspase 2, 3, 8, and 9 activities were signifi-
cantly increased in the control group subjected to 120 min-
utes of ischemia as compared with the 30-minute ischemic
controls (4.5-, 4.1-, 2.1-, and 2.4-fold increase in caspase 2,
3, 8, and 9, respectively; Figure 2). After 30 minutes of
ischemia, caspase 9 activity—but not caspase 2, 3, or 8
activity—significantly decreased in the PKC regulator–
treated group as compared with the control group (Figure 2).
However, we found that PKC regulator treatments de-
Figure 2. Selective PKC regulators reduce caspase 2
ischemia-reperfusion injury to transplanted hearts su
activity. B, Caspase 3 activity. C, Caspase 8 activity. D
for each ischemic time); open columns, PKC regulato
significant. Values obtained from naive hearts of PVG
Mean  SE values are shown.creased caspase 2, 3, and 9 activity by 42%, 88%, and 67%,
The Journal of Thoracicrespectively, but not caspase 8 activity, as compared with
the 120-minute ischemic controls (Figure 2). Furthermore,
treatment with PKC regulators reduced caspase 2, 3, and 9
activity in the 120-minute ischemic group to the levels found in
hearts subjected to only 30 minutes of ischemia. Therefore, in
the transplanted heart subjected to prolonged ischemia, treat-
ment with PKC activator and PKC inhibitor reduces caspase
2– and 9–mediated cardiomyocyte apoptosis to the levels
observed after only a short ischemic period.
Treatment With PKC Regulators During Prolonged
Ischemia Reduces the Resultant Proinflammatory
Response of Ischemia-Reperfusion Injury
Ischemia-reperfusion injury also produces a proinflammatory
environment that includes an influx of injurious cytokines and
chemokines.5 To determine whether treatment with PKC reg-
ulators reduces the inflammatory response during prolonged
ischemia, we examined neutrophil-produced MPO. Neutro-
phils are predominant effector cells in the local inflammatory
response.18 We also determined the levels of the proinflam-
nd 9 activity, but not caspase 8 activity, induced by
ted to 30 or 120 minutes of ischemia. A, Caspase 2
pase 9 activity. Closed columns, Control group (n  6
ated group (n  6 for each ischemic time); N.S., not
(control; no ischemia) served as a reference (n  4)., 3, a
bjec
, Cas
r–tre
ratsmatory cytokines and chemokines TNF-, IL-1, and MCP-
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and the tested proinflammatory cytokines increased by 1.7-fold
in the 120-minute ischemic controls compared with the 30-
minute ischemic controls. The production of TNF- signifi-
cantly decreased in both PKC regulator–treated groups,
whereas the production of IL-1 and MCP-1 decreased (41%
and 35%, respectively) only in the 120-minute ischemic, PKC
regulator–treated group (Figure 3). It is important to note that
there were no significant differences in these inflammatory
responses between the PKC regulator–treated group subjected
to 120 minutes of ischemia and the 30-minute ischemic control
group (Figure 3). In addition to reducing caspase 2 and 9, PKC
regulator treatment during prolonged ischemia also reduces
cardiomyocyte apoptosis by minimizing the proinflammatory
response, as measured by the reduction in cytokine levels.
Treatment With PKC Regulators Significantly Inhibits
GCAD Stimulated by Prolonged Ischemia
There was no early graft loss due to acute rejection until 90
Figure 3. Selective PKC regulators reduce myeloperox
tion induced by ischemia-reperfusion injury to transpla
MPO activity. B, TNF- production. C, IL-1 production.
(n  6 for each ischemic time); open columns, PKC re
not significant. Values obtained from naive hearts of P
4). Mean  SE values are shown.days after transplantation. We first demonstrated that pro-
1164 The Journal of Thoracic and Cardiovascular Surgery ● Malonged ischemia during organ procurement increases GCAD,
as measured 90 days after transplantation (Figure 4). A 3.2-
fold increase in the luminal narrowing percentage, a 4.5-fold
increase in the intima-media ratio, and a 2.5-fold increase in
the diseased vessel percentage were evident. Conversely, treat-
ment with PKC regulators during organ procurement and at
reperfusion inhibited GCAD in the cardiac allografts subjected
to 120 minutes of ischemia, decreased the percentage of lumi-
nal narrowing by 78%, decreased the intima-media ratio by
58%, and decreased the percentage of diseased vessels by 68%
90 days after transplantation (Figure 4).
Discussion
In this study, we examined the acute consequences of PKC
and PKC treatment during brief (30 minutes) or prolonged
(120 minutes) procurement ischemia and the chronic results
on the development of GCAD. These PKC regulators re-
duce ischemia-reperfusion injury by 2 distinct means: an
(MPO) activity and proinflammatory cytokine produc-
hearts subjected to 30 or 120 minutes of ischemia. A,
CP-1/CCL-2 production. Closed columns, Control group
or–treated group (n  6 for each ischemic time); N.S.,
ats (control; no ischemia) served as a reference (n idase
nted
D, M
gulat
VG rPKC activator delivered before and early during ischemia
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delivered at reperfusion has an antiapoptotic effect. We
Figure 4. Selective PKC regulators reduce GCAD in ca
A, Representative sections of cardiac allografts staine
control group with 30 minutes of ischemia (a), the PKC
the control group with 120 minutes of ischemia (c),
ischemia (d). Note that marked fibrointimal thickening
human GCAD, were observed in the control group with
and preserved vessel lumen were observed in the
regulator–treated groups with 30 and 120 minutes of is
Note that compared with parameters in the control gr
were significantly reduced in the PKC regulator–trea
transplantation. In addition, The GCAD indexes of the
did not differ significantly from those of the control gr
group (n  8 for each ischemic time); open columns, P
N.S., not significant. Mean  SE values are shown.found that in control animals, 120 minutes of ischemia
The Journal of Thoracicincreased cardiomyocyte apoptosis; caspase 2, 3, 8, and 9
activity; inflammatory cytokine production; and neutrophil
allografts subjected to 30 or 120 minutes of ischemia.
th Elastica Van Gieson for evaluation of GCAD in the
ulator–treated group with 30 minutes of ischemia (b),
he PKC regulator–treated group with 120 minutes of
uminal narrowing, morphologically resembling typical
inutes of ischemia. In contrast, less intimal thickening
ol group with 30 minutes of ischemia and the PKC
ia. B, Morphometric assessment of cardiac allografts.
with 120 minutes of ischemia, all 3 GCAD parameters
roup with 120 minutes of ischemia at 90 days after
regulator–treated group with 120 minutes of ischemia
with 30 minutes of ischemia. Closed columns, Control
gulator–treated group (n  6 for each ischemic time);rdiac
d wi
reg
and t
and l
120 m
contr
chem
oup
ted g
PKC
oup
KC reinfiltration into the allografts as compared with 30 minutes
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with prolonged ischemia correlated with increased GCAD
measured 90 days after transplantation. In contrast, com-
bined treatment with the PKC-specific inhibitor V1-1 and
the PKC-specific activator RACK significantly sup-
pressed ischemia-reperfusion injury and resulted in an ap-
proximately 70% reduction in GCAD. The protective effect
of these PKC regulators was more significant in the pro-
longed-ischemia group. In addition, treatment with these
PKC regulators reduced all the parameters related to isch-
emia-reperfusion injury and GCAD after prolonged isch-
emia to the level of those observed after the short period of
ischemia. The PKC regulator–treated group with prolonged
ischemia showed an approximately 70% decrease in the
production of the proinflammatory cytokine TNF- and an
approximately 40% decline in IL-1 and MCP-1/CCL-2.
Significant decreases were also observed in MPO activity,
cardiomyocyte apoptosis, and caspase 2, 3, and 9 activity. It
is important to note that the reduction in ischemia-reperfu-
sion injury observed 4 hours after transplantation correlated
with a reduction in the development of GCAD; there was a
70% decline in disease severity in the PKC regulator–
treated group as compared with the control group.
Activation of PKC is associated with inhibition of pro-
liferation, cell-cycle arrest, enhanced differentiation, and/or
accelerated apoptosis in several nonheart cell lines.20 Zhao
and associates6 have shown that the number of apoptotic
cells is increased during reperfusion, that apoptosis may be
accelerated by the process of reperfusion, and that inhibition
of PKC reduces reperfusion injury to the myocardium by
inhibiting apoptosis.21 Our previous study with a porcine
model of acute myocardial infarction demonstrated that the
cardioprotective effects of PKC inhibitor may result from
inhibiting cell signaling, thereby implicating this isozyme in
mediating apoptosis.19 In this study, caspase 3 and 9 activity
was significantly reduced in the PKC regulator–treated
group with prolonged ischemia, whereas no significant re-
duction in caspase 8 was observed in PKC regulator–treated
group after 30 and 120 minutes of ischemia. Thus, apoptosis
in the cardiac allograft was reduced mainly by inhibition of
the caspase 9–mediated proapoptotic pathway.
Oxygen-derived free radicals are directly implicated in
pathologic apoptosis.22 We observed a significant increase
in both superoxide production and cardiomyocyte apoptosis
with prolonged ischemia in comparison to that with a short
ischemic period. However, there was no significant reduc-
tion in superoxide production in the PKC regulator–treated
group in comparison to the saline-treated control group
subjected to either 30 or 120 minutes of ischemia. This
suggests that this early burst of superoxide production is
independent of PKC and PKC.
The role of caspase 2 in apoptosis is still unclear,23 but
caspase 3 activation by caspase 2 has been reported to
1166 The Journal of Thoracic and Cardiovascular Surgery ● Mainvolve caspase 9 activation.24 We observed a significant
increase in caspase 2, 3, and 9 activity after prolonged
ischemia, and this was significantly decreased after PKC
regulator treatment. This is the first report that shows a
suppressive effect by selective PKC regulators on caspase 2
activity in an in vivo heart transplantation model. However,
the mechanistic basis for interactions of PKC and PKC
isozymes and caspase 2 activation, and interactions of
caspase 2 and downstream caspases, in our experimental
model remains to be elucidated.
Most importantly, GCAD was significantly reduced at 90
days after transplantation after PKC regulator treatment.
This reduction after 120 minutes of ischemia was compa-
rable to the level of GCAD after 30 minutes of ischemia.
Because the half-life of the PKC-regulation peptides is very
short, the reduction in GCAD that we observed after the
120-minute ischemia most likely occurred because of the
acute reduction in ischemia-reperfusion injury in the early
phase. The early cell-protective effect might have resulted
in decreased production of proinflammatory cytokines in the
cardiac allograft, which in turn led to a decreased GCAD.
Although this study used an allogenic model of heart
transplantation as a model of cardiac transplantation in
humans, the ischemic period of 120 minutes is shorter than
the mean ischemic time in humans (3.1 hours).1 Neverthe-
less, GCAD progression in the rodent model is accelerated
relative to that in humans16 and therefore may be useful to
begin assessing new therapies to prolong graft survival. In
addition, this model examined sequential treatment of the
donor heart with the PKC activator in the cardioplegic
solution followed by treatment with the PKC inhibitor in
the recipient rat just before reperfusion. The study did not
determine the optimal timing of treatment or the concentra-
tion of these peptides to obtain optimal protection of
GCAD. Although these PKC regulators did not exert sig-
nificant effects on most of the measured parameters as
compared with the saline-treated controls, in allografts sub-
jected to a short ischemic insult (30 minutes), there were
trends of reduction in ischemia-reperfusion injury and
GCAD in the PKC regulator–treated group as compared
with saline-treated controls. The differences between the
PKC regulator–treated group and the saline-treated controls
became more apparent with increased ischemia-reperfusion
injury and GCAD caused by prolonged ischemia (120 min-
utes).
Because the goal for this study was to design a clinically
relevant protocol, the side effects of the PKC inhibitor,
which was delivered systemically to the recipient before
reperfusion, should be discussed. Previous study has shown
that a single bolus dose of PKC inhibitor (TAT47-57/
V1-1) administered by intracoronary delivery in pigs (5
g/kg) resulted in no toxic effects in the kidney, spleen,
liver, or lung.19 Furthermore, PKC knockout mice are
y 2005
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free-radical formation in the vein graft response (there was
a decrease in this damage),10 thus supporting our observa-
tion on the nontoxic effect of PKC inhibitor, but the benefit
for vasculopathy in the graft.
In conclusion, our results suggest that GCAD—and pos-
sibly organ failure induced by prolonged ischemia of the
donor heart—may be inhibited by combined treatment with
an PKC activator and a PKC inhibitor in clinical cardiac
transplantation.
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